Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)

Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) said its China VIE, Shuhai Jingwei, completed FDA establishment registration and device listing for the NeuroVibe acoustic biofeedback system (NV-02, NV-03). The devices were listed as Class II 510(k)-exempt biofeedback medical devices under FDA product code HCC. Datasea said this supports U.S. commercialization planning; listing is not FDA approval.

Original reporting
Published Aug 11, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k) — source image
Decision brief

The 30-second read

$DTSSBullishMed
01

Why it matters

The company frames FDA establishment registration and device listing as moving NeuroVibe from R&D toward a regulated product platform for US commercialization, but the release explicitly disclaims FDA approval/clearance.

02

Market read

This is a concrete regulatory milestone for a specific device platform, but it is not FDA clearance, so traders may treat it as a de-risking step rather than a definitive commercialization green light.

03

What to watch

Traders should watch for evidence of reimbursement, clinical outcomes, manufacturing readiness, and whether any additional FDA steps are required beyond listing for the intended claims.

Relevance 7/10Novelty 7/10Timing: today, same-day regulatory milestone announcement

Background

Datasea is developing an acoustic AI and non-invasive BCI biofeedback system (NeuroVibe) and is using a China VIE structure for FDA-related activities.

Company-level read

Ticker impact

$DTSSBullishMedium confidence
Context

Datasea says its China VIE Shuhai Jingwei completed FDA establishment registration and listed NeuroVibe NV-02/NV-03 as Class II 510(k)-exempt biofeedback devices.

Expected impact

Near-term upside bias possible on commercialization optimism, with follow-through likely dependent on subsequent clinical/market validation and any later FDA clearance steps.

Evidence & confidence

The article discloses a fresh FDA-related administrative milestone (establishment registration and product listing) and specific product codes (HCC) and device class (Class II 510(k)-exempt). However, it explicitly states this is not FDA approval/clearance, limiting immediate fundamental re-rating.

Market effects

Supports the broader non-invasive neurotechnology and biofeedback device commercialization narrative, but does not establish clinical efficacy or clearance.

US regulatory pathway progress for a China-based VIE may improve perceived access to the US medtech market.

Could strengthen Datasea’s positioning for global adoption claims, though the milestone is US-focused and administrative rather than approval-based.

Counterpoint

Because the release stresses no FDA approval/clearance, the market may already price in “paper” regulatory progress, limiting sustained impact.

Key entities

  • Datasea Intelligent Technology Ltd.

    NASDAQ-listed company announcing FDA establishment registration and device listing for its NeuroVibe biofeedback system via its China VIE.

  • Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd.

    Datasea’s variable interest entity in China that completed FDA establishment registration and device listing for NeuroVibe products NV-02 and NV-03.

  • NeuroVibe Biofeedback System (NV-02, NV-03)

    Non-invasive biofeedback system listed under FDA product code HCC as Class II 510(k)-exempt devices.

  • FDA product code HCC

    The FDA product code under which NeuroVibe NV-02 and NV-03 are listed as Class II 510(k)-exempt biofeedback devices.

Related articles

$AMZNHigh

Data Center Backlash Hits Amazon Hardest in Ohio

Amazon's $17B Ohio data center plan is at risk after voters approved measures to limit development, affecting 3 projects and 1.8GW of power. Amazon shares rose 0.43% premarket. The company plans $23B investment in Ohio by 2030, with most capital spending going to AI infrastructure, according to the Financial Times and Regbase data.

$SMCIMed

Wife of Senior Nvidia Executive Caught Up in Alleged AI Chip Smuggling Scandal

U.S. prosecutors charged three individuals tied to Super Micro Computer with allegedly smuggling $2.5B in AI servers to China, violating export controls. Super Micro's servers use Nvidia GPUs, placing it in the supply chain under U.S. scrutiny. A shareholder lawsuit alleges former exec Cenly Chen knew of illicit sales, which the company denies. Short-seller Muddy Waters raised questions about Chen's ties to an Nvidia executive, but no criminal charges have been filed against either.